



science & innovation

Department:
Science and Innovation
REPUBLIC OF SOUTH AFRICA

Implemented by

giz Deutsche Gesellschaft
für Internationale
Zusammenarbeit (GIZ) GmbH

Competitive Call for Proposals Applicant Information Pack

**Grants for enhancing manufacturing capacities
and access to vaccines, medicines, and health
technologies in South Africa**

SAVax Programme: Vaccines for Africa: Roll-out and Production
of Vaccines in South Africa

Table of Contents

| | |
|---|-----------|
| BACKGROUND | 3 |
| KEY INFORMATION | 5 |
| PROJECT FLOW DIAGRAMS..... | 6 |
| <i>Virtual Information Sessions</i> | 7 |
| <i>Application Deadline</i> | 7 |
| TECHNICAL SCORING AND SHORTLISTING | 7 |
| <i>Eligibility Requirements</i> | 7 |
| <i>Technical Scoring</i> | 8 |
| <i>Interview and Site Visits</i> | 8 |
| <i>Project Selection</i> | 9 |
| FOCUS AREAS & SCOPE..... | 10 |
| RULES FOR THIS CALL FOR PROPOSALS | 12 |
| GENERAL PROVISIONS | 12 |
| NUMBER OF APPLICATIONS AND GRANTS PER APPLICANTS..... | 13 |
| FORWARDING OF FUNDS TO THIRD-PARTY RECIPIENTS & FUNDS FOR DIRECT SUPPORT OF THIRD-PARTY BENEFICIARIES . | 13 |
| RIGHTS OF USE | 14 |
| VISIBILITY | 15 |
| ETHICS CLAUSES AND CODE OF CONDUCT..... | 15 |
| PROJECT TEMPLATES..... | 16 |
| PROJECT PROPOSAL AND APPLICATION..... | 16 |
| BUDGET TEMPLATE..... | 17 |
| APPENDICES..... | 18 |
| APPENDIX 1: CALL FOR PROPOSALS | 18 |
| APPENDIX 2: VIRTUAL INFORMATION SESSIONS & AGENDA..... | 20 |
| APPENDIX 3: FREQUENTLY ASKED QUESTIONS | 21 |
| APPENDIX 4: KOBO TOOLBOX INSTRUCTIONS..... | 23 |

Background

The [Deutsche Gesellschaft für Internationale Zusammenarbeit \(GIZ\) South Africa, Lesotho and Eswatini](#) implements the SAVax programme (Vaccines for Africa: Roll-out and Production of Vaccines in South Africa). SAVax is funded by the [Bundesministerium für wirtschaftliche Zusammenarbeit und Entwicklung \(BMZ\)](#) and co-funded by the [European Union \(EU\)](#). It supports local manufacturing capacities in South Africa to enhance access to quality, safe, effective and affordable vaccines, medicines, and health technologies. On behalf of the European Union and the BMZ, the GIZ SAVax programme implements the Joint Action for Enhancing Manufacturing Capacities and Access to Vaccines, Medicines and Health Technologies in South Africa. SAVax is therefore integral to the implementation of the [Team Europe Initiative MAV+ \(Manufacturing and Access to Vaccines, Medicines and Health Technology Africa\)](#) in South Africa and extends from ongoing efforts by the BMZ for sustainable production of vaccines and their distribution in South Africa.

The COVID-19 pandemic highlighted the inequality in vaccine access, emphasizing the urgent need to enhance local manufacturing capacity for vaccines, medicines, and health technologies in Africa to improve pandemic preparedness and ensure supply chain security. Consequently, there has been a surge in both continental and global political support to develop pharmaceutical production and bolster Africa's ability to respond to pandemics. These efforts are spearheaded by the [African Union's \(AU\) Partnerships for African Vaccine Manufacturing \(PAVM\)](#) and more recently through the Platform for Harmonised Health Products Manufacturing (PHHPM). The emergence of new pathogens and antimicrobial resistance further exacerbates the complexity of healthcare delivery. Additionally, climate change and shifting epidemiological patterns of communicable diseases as well as the increasing burden of Non-Communicable Diseases (NCDs), such as cardiovascular diseases, diabetes, and cancer, place additional strain on healthcare resources with significant long-term health and fiscal consequences. Addressing these challenges requires innovative approaches and collaborative efforts to develop effective vaccines, therapeutics, and diagnostics/health technologies.

Collaboration between academia/research institutions and private sector partners is paramount in driving bio-innovation forward. Academia/research institutions bring deep scientific expertise, research infrastructure, and a commitment to advancing knowledge, while the private sector offers resources, commercialization capabilities, and market insights. By harnessing the strengths of both sectors, collaborative efforts can accelerate the translation of research findings into tangible products and solutions that benefit public health. Moreover, such partnerships facilitate knowledge exchange, technology transfer, and skills development, ultimately fostering a culture of innovation and entrepreneurship within the South African healthcare ecosystem. South Africa is well placed to contribute to the continental efforts being a front-runner in research and manufacturing of vaccines, pharmaceuticals, and diagnostics/health technologies. South Africa has a vibrant academic research and innovation scene in the biotechnology arena, hosts some of the top universities in Africa and is strong in many areas of the research and development (R&D) needed for the development of vaccines,

therapeutics, and diagnostics. Furthermore, it already has a sizeable and functional industry with companies that supply segments of the local and regional market and a strong regulator (SAHPRA).


Key Information

| | |
|---------------------------------------|--|
| Specific Objectives | <ul style="list-style-type: none"> • Stimulate collaborative research and development efforts between academia/research institutions and private sector partners. • Support the development of innovative vaccines, pharmaceuticals, and diagnostics and healthcare technologies that address healthcare challenges in South Africa. • Foster the translation of research findings into tangible products, market access, and solutions that benefit public health. |
| Target Recipients | Partnerships between: universities/higher education institutions, research institutions, and private sector entities from the pharmaceutical, biotechnological, and biomanufacturing sectors. |
| Funding Amount | Up to EUR 350 000 |
| Project Duration | Up to 24 Months |
| Virtual Information Session(s) | 30.08.2024 16.09.2024 |
| Application Deadline | 30 September 2024 |
| Interviews & Site Visits | 28 October 2024 – 01 November 2024 |
| Project Selection | 01 November 2024 |
| Project Commencement | ca. 01.05.2025 |

These timelines are indicative and for planning purposes and are likely to change. Please review updates on the website.

Project Flow Diagrams

Figure 1: Project Flow Diagram



Virtual Information Sessions

Two virtual information sessions will be convened. The purpose of these, will be to

- Explain background to the Call for Proposals.
- Describe the nature of relationship between universities/research institutions, and private sector partners.
- Address questions related to application process and selection criteria.
- Address questions related to communications.
- Address questions related to budgeting, financial management and requirements.

Additional queries can be directed to the project team via the dedicated email address (savajointaction@giz.de).

Please see **Appendix 2: Virtual Information Sessions & Agenda** and **Appendix 3: Frequently Asked Questions**.

Application Deadline

Applications and supporting documents must be submitted via the [KOBO Toolbox](#) platform. Submissions will close at **17:00 close of business (COB) SAST on Monday 30 September 2024**.

Templates to be completed and uploaded are available at:

<https://www.giz.de/en/worldwide/154595.html>

Technical Scoring and Shortlisting

Eligibility Requirements

- Fully completed application with submission of ALL documents requested in the online application. Any applications that are not complete or do not have the requisite documents attached will be excluded.
- Applications should comprise of partnerships or collaborations including at least one academic/research institution and one private sector partner.
 - o Either entity can be the lead applicant.
- The Lead Applicant must be based in South Africa.
- The expected contribution from consortia shall be at least 15% of total project costs under this call for proposals. This contribution may be in salaries, own financial contribution, company/initiative space/rooms, exploratory costs, consultants, marketing and distribution costs, or similar contribution. The recipient must demonstrate sufficient cash flow capacity to provide its own financial contribution.
- Partner organisations cannot be a subsidiary of a company based in the EU. In other words, no part of the entity, can have any tax liability in Germany or the EU.
- Projects should align with the focus areas and scope described in this call.

Technical Scoring

The following criteria will be utilised for the weighted assessment of proposals. Prospective recipients are encouraged to read the descriptions and guiding prompts in detail.

- **Technical Merit (weighting of 35%)**
Assessment of the feasibility, novelty, and scientific rigor of the proposed project. Projects should have well-defined methodologies, supported by strong preliminary data, and demonstrate innovative approaches to addressing healthcare challenges.
- **Impact (weighting of 20%)**
Evaluation of the potential impact of the proposed project on public health, particularly in the African context. Projects targeting prevalent diseases in South Africa, with the potential to significantly improve health outcomes, reduce disease burden, or enhance healthcare delivery.
- **Innovation (weighting of 15%)**
Evaluation of the creativity and innovativeness of the proposed solution. Projects are encouraged to introduce novel technologies, methodologies, or approaches that have the potential to disrupt existing paradigms or address unmet needs in healthcare.
- **Sustainability Readiness (weighting of 15%)**
Assessment of plans for sustaining and scaling the proposed solution beyond the project period. Projects should incorporate strategies for long-term sustainability and scalability, such as business models, partnerships with local stakeholders, or plans for regulatory approval and market access, and plans for regulatory approval.
- **Gender and Inclusion Initiatives (weighting of 10%)**
Assessment of measures to address gender equality and similar initiatives related to representation, inclusivity, and impact.
- **Environmental Impact (weighting of 5%)**
Assessment of measures to address climate change as they relate to the project proposal. Projects should, as relevant, include strategies related to; environmental impact reduction, sustainable resource use, energy efficiency and renewable energy use, climate resilience and adaptation, regulatory compliance and social responsibility.

Interview and Site Visits

- Based on the aforementioned scoring, prospective recipients who have been shortlisted will be invited to host an in-person interview and site visit.
- This is anticipated to commence from the 28th of October 2024 to the 1st of November 2024.
- Prospective recipients should prepare for the possibility of an interview during this period unless otherwise informed that their application was unsuccessful.

Project Selection

- Final project selection will be determined based on a combination of technical scoring and site visits and interviews.
- Formal letters will be distributed inviting prospective candidates to go through the commercial and legal suitability assessment, and to participate in the wider technical assistance activities.
- Letters of regret will be distributed to candidates that did not make it through the interview stage.
- It is anticipated that these letters will be distributed from 04 November 2024.

Focus Areas & Scope

This call seeks to solicit proposals that intend to undertake industrial research and/or translate research into product development and market introduction.

- Proposed projects must focus on the development of vaccines, therapeutics, or diagnostics/health technologies or the upstream/downstream contribution to the development thereof.
- Projects should comprise partnerships between research institutes/universities, and private sector collaborators.
- Emphasis is placed on 'last mile' support to companies and institutions that are advanced in their innovation, research and technological journey, and are close to market readiness.
- Projects should highlight the pipeline, their specific contribution (and potential bottlenecks) from research and development to product development and market readiness, to scaling manufacturing.
- Specifically, therefore SMME's are a key target group, especially those that require support to accelerate towards market readiness.
- Proposals should contribute to the strengthening of capacity in manufacturing, and research and development, leveraging innovation in the biotechnology, pharmaceutical, and biomanufacturing sectors, while making a concerted contribution to the public health impact in Africa.

We encourage:

- Product development (vaccines, pharmaceuticals, diagnostics, and health technologies), commercial manufacturing, and market access initiatives.
- Innovations in product formulation and development for underserved patient groups.
- Application of new technologies in pharmaceutical manufacturing in general.
- Formulation innovations (including dosage forms and rapid diagnostics).
- Clinical validation of drugs, vaccines and diagnostics as well as Phase 1, or clinical validation/bioequivalence studies/trials.
- Product application and/or studies with generalisable research findings.
- Proposals that include cost-effectiveness and/or market analyses.
- Inclusion of primary and/or secondary data approaches.
- Robust innovative technologies that advance product development and/or research, tailored for humanitarian/emergency settings.

We exclude:

- Systematic reviews.
- Observational studies.
- Formative research (those that need to conduct preliminary studies before a larger research study can be designed or product be developed).

Core areas within the biotechnology, pharmaceutical, and biomanufacturing sectors that are of particular interest are presented in Figure 2, **including but not limited to**;




Figure 2: Key Intersections - Biopharmaceutical Sector

Therapeutics:

- Generics, Gene therapies, Cell based therapies, Recombinant proteins, Biosimilars.

Biologicals:

- Enzymes for medical diagnostics, Enzymes for industrial processes, Insulin.

Vaccines:

- Routine vaccines, mRNA, Antigens, Adjuvants, Excipients.

Diagnostics/Health Technologies:

- Diagnostic reagents, Diagnostic assay kits, Molecular diagnostic tests.

Rules for this Call for Proposals

General Provisions

The Recipient shall observe the principles of proper accounting in the implementation of the Project and ensure project-specific account settlement and documentation. The Recipient shall comply with the guidelines on financial processing.

Please refer in detail to financial requirements and procurement guidelines. The budget submitted on the application form should mirror the [Budget Template](#). Both need to be submitted as part of the application. Additional resources, including the [Guidelines for Grant Recipients on the Financial Processing of Grant Agreements](#), can be found on the GIZ website related to [Financing](#).

The awarding of a grant is always subject to the condition that the checks preceding the signing of the grant contract do not reveal problems requiring changes to the budget (such as arithmetical errors, inaccuracies, unrealistic costs and/or ineligible costs). The checks may give rise to requests for clarification and may lead to modifications or reductions to address such mistakes or inaccuracies. It is not possible to increase the grant as a result of these corrections. It is therefore in the applicants' interest to provide a **realistic and cost-effective budget**.

The total amount of financing cannot exceed EUR 350 000. The expected contribution from consortia shall be at least 15% of total project costs under this call for proposals. This contribution may be in salaries, own financial contribution, company/initiative space/rooms, exploratory costs, consultants, marketing and distribution costs, or similar contribution. The total budget including the consortia contribution (>EUR 52 500) is therefore at least EUR 402 500.

Eligible costs: For the implementation, the following costs are **eligible**. These should all be verifiable project-specific costs and not represent general company/initiative operating or other non-project specific costs:

- Staff costs
- External service
- Transport costs/travel expenses
- Procurement of materials and
- Other costs/consumables
- Funds for direct support to third party beneficiaries
- Pro rata local project costs
- Administrative costs
- Forwarding of funds to third party recipients

In particular, but not exclusively, the following costs are **ineligible**:

- Bonuses, provisions, reserves or non-remuneration related costs
- Duties, taxes and charges, including VAT, that are recoverable/deductible by the applicant

- Return of capital
- Debts and debt service charges
- Provision for losses, debts or potential future liabilities
- Costs of purchase of land or buildings

Number of applications and grants per applicants

- The Lead Applicant may not submit **more than one application** under this call for proposals.
- The Lead Applicant may not be awarded **more than one grant** under this call for proposals.
- The Lead Applicant **may not be a Co-Applicant** in another application at the same time, under this call for proposals.
- A Co-Applicant may not be the Lead- or Co-Applicant in **more than one** application under this call for proposals.
- A Co-Applicant **may not be awarded more than one grant** under this call for proposals.

Forwarding of funds to third-party recipients & funds for direct support of third-party beneficiaries

The forwarding of funds to third-party recipients or disbursement of funds to third-party beneficiaries is only permissible if provided for in the Estimated Budget and in the Project Proposal.

Third-party recipients are third parties to which the Recipient forwards part of the Grant for joint (partial) implementation of the Project.

Third-party beneficiaries are third parties that receive funds from the Recipient as the direct and final beneficiary of the Project.

Prior to forwarding funds for the first time, the Lead Applicant must conduct an appropriate due diligence assessment of third-party recipients. A positive assessment of the integrity and eligibility of the respective third-party recipient, taking into consideration the public-benefit purpose of the project, is a prerequisite for forwarding funds. The Lead Applicant must document the assessment and make this documentation available to GIZ. The required information for each co-applicant is detailed on the Kobo Toolbox submission.

The Lead Applicant must demonstrate to GIZ that forwarded funds have been used properly by submitting appropriate financial reports from the third-party recipient and, upon request by GIZ, copies of vouchers.

Disbursements by the Lead Applicant to third-party recipients must be made in accordance with the Grant Agreement and be shown separately in the financial report submitted by the Lead Applicant. The Lead Applicant undertakes to verify the financial report submitted by the third-party recipient in accordance with the terms of the Grant Agreement and to submit this financial report to GIZ together with the findings of its own assessments.

In addition to the conditions stipulated in the Grant Agreement related to the forwarding of funds to third-party recipients or disbursement of funds to third-party beneficiaries, the Lead Applicant must ensure when disbursing funds to third-party beneficiaries that:

- the cost effectiveness and appropriateness of the payment amount are verified and documented;
- the criteria for selection are established prior to the selection process and the criteria of equal opportunities, transparency and freedom from any form of discrimination are considered. The selection shall be justified and documented accordingly;
- the disbursement made by the Lead Applicant and receipt of the funds by the third-party beneficiary must be documented in text form. The specific obligations of third-party beneficiaries to provide evidence can be found in the [Budget Template](#).

For the award and procurement of materials and equipment, construction services or other services ('Procurements') to be financed in whole or in part by the Grant, the Lead Applicant shall comply with the provisions on procurement procedures as set out in the Procurement guidelines. Applicants are encouraged to review the [Guidelines for Grant Recipients on the Financial Processing of Grant Agreements](#), which can be found on the GIZ website related to [Financing](#).

Rights of Use

For the purpose of optimising business activities as set out in GIZ's Articles of Association and securing the work results for public-benefit purpose, the Lead Applicant grants GIZ, free of charge, an irrevocable, simple, worldwide and transferable right of use to all work results which are created or procured in connection with implementation of the Project and financed wholly or partially out of the Grant, with particular regard to the reports produced pursuant to the Grant Agreement, studies and documents; GIZ is entitled to exercise this right of use without restrictions on time or content in fulfilment of its public-benefit purpose as stated in its articles of association. At the request of GIZ, the Lead Applicant shall provide GIZ with a copy of the materials available. GIZ is entitled to grant third parties simple sub-rights of use free of charge in fulfilment of its public-benefit purpose as stated in its articles of association.

Visibility

The applicants must take all necessary steps to publicise the fact that the BMZ and European Union have financed the action as part of the GIZ SAVax programme and under the Team Europe Initiative MAV+. As far as possible, actions that are wholly or partially funded by the Grant must incorporate information and communication activities designed to raise the awareness of the results and the impact of this support.

Ethics Clauses and Code of Conduct

a) Absence of conflict of interest

The applicant must not be affected by any conflict of interest and must have no equivalent relation in that respect with other applicants or parties involved in the actions. Any attempt by an applicant to obtain confidential information, enter into unlawful agreements with competitors or influence the selection committee or the contracting authority during the process of examining, clarifying, evaluating and comparing applications will lead to the rejection of its application. Any questions on the process, evaluation criteria or status of the application must be submitted to GIZ through savaxjointaction@giz.de.

b) Respect for human rights as well as environmental legislation and core labour standards

The applicant and its staff must comply with human rights. In particular and in accordance with the applicable act, applicants who have been awarded contracts must comply with the environmental legislation including multilateral environmental agreements, and with the core labour standards as applicable and as defined in the relevant International Labour Organisation conventions (such as the conventions on freedom of association and collective bargaining; elimination of forced and compulsory labour; abolition of child labour).

c) Anti-corruption and anti-bribery

The applicant shall comply with all applicable laws and regulations and codes relating to anti-bribery and anti-corruption. GIZ reserves the right to suspend or cancel project financing if corrupt practices of any kind are discovered at any stage of the award process or during the execution of a contract. For the purposes of this provision, 'corrupt practices' are the offer of a bribe, gift, gratuity or commission to any person as an inducement or reward for performing or refraining from any act relating to the award of a contract or execution of a contract already concluded with the contracting authority.

Project Templates

Below are details related to the project templates associated with the Competitive Call for Proposals.

These include;

- Project proposal and application templates.
- Budget templates.

Project Proposal and Application

Project proposals and applications are to be submitted through the [Kobo Toolbox](#) platform. Please see description below about accessing and navigating the Kobo Toolbox platform.

There are a total of 9 sections to the application form which culminates in the project proposal. Please review the instructions carefully and ensure the appropriate supporting documentation are uploaded along with the completed application form.

1. Instructions
2. Lead Applicant Details
3. Co-Applicant Details
4. Organisational Support
5. Project Details
6. Logical Framework Matrix
7. Budget and Financing
8. Commercial Suitability Assessment – Lead Applicant
9. Commercial Suitability Assessment – Co-Applicant

Budget Template

The expected contribution from consortia shall be at least 15% of total project costs under this call for proposals. This contribution may be in salaries, own financial contribution, company/initiative space/rooms, exploratory costs, consultants, marketing and distribution costs, or similar contribution.

The recipient must demonstrate sufficient cash flow capacity to provide its own financial contribution. Templates related to the financing of the project can be accessed from the links below.

The budget submitted on the application form should mirror the [Budget Template](#). Both need to be submitted as part of the application.

Additional resources, including the [Guidelines for Grant Recipients on the Financial Processing of Grant Agreements](#), can be found on the GIZ website related to [Financing](#).

Appendices

Appendix 1: Call for Proposals



GRANTS FOR ENHANCING MANUFACTURING CAPACITIES AND ACCESS TO VACCINES, MEDICINES, AND HEALTH TECHNOLOGIES IN SOUTH AFRICA

CALL FOR PROJECT PROPOSALS

The GIZ (Deutsche Gesellschaft für Zusammenarbeit) SAVax programme on behalf of the BMZ and the European Union, together with the South African National Department of Science and Innovation (DSI), launches this Competitive Call for Proposals to support innovation and product development by consortia of private sector entities and research institutions.

The selected projects should support the development of innovative vaccines, pharmaceuticals, and diagnostics and/or technologies that address healthcare challenges in South Africa and the African context. In addition, they should foster the translation of research findings into tangible products, market access, and solutions that benefit public health.

For this call, proposals are welcomed, but not limited to, projects focusing on the following:

(i) Research and product development of vaccines, pharmaceuticals, diagnostics, and health technologies, this includes drug/product discovery, as well as upstream/downstream contributions to the development thereof. (ii) Clinical validation of drugs, vaccines and diagnostics as well as clinical validation/bioequivalence studies/trials. (iii) Innovations and application of new technologies in product formulation and development for underserved patient groups.

The SAVax Joint Action project will allocate grants up to EUR 350,000 to selected eligible proposals. Eligible applicants comprise consortia of private companies and public institutions (including universities and research centres) located in South Africa.

The expected contribution from consortia shall be at least 15% of total project costs under this call for proposals. This contribution may be in salaries, own financial contribution, company/initiative space/rooms, exploratory costs, consultants, marketing and distribution costs, or similar contribution. Eligible consortia are expected to complete the project within twenty-four (24) months, which must be reflected in the proposal.

Further detailed information and downloads are available at <https://www.giz.de/en/worldwide/154595.html>. Interested applicants must submit their proposal through the application platform.

The submission of applications deadline is **17:00 close of business (COB) SAST on Monday 30 September 2024.**

Queries can be directed to: savaxjointaction@giz.de.

Appendix 2: Virtual Information Sessions & Agenda

| | |
|---|---|
| <p>Session 1 Topic: SAVax Joint Action - Call for Proposals Information Session (1)</p> <p>Date: 30 August 2024</p> <p>Time: 14:00 - 15:30 (SAST)</p> <p>Meeting Details: MS Teams Link Meeting ID: 320 246 996 753 Passcode: QEmgrv</p> | <p>Session 2 Topic: SAVax Joint Action - Call for Proposals Information Session (2)</p> <p>Date: 16 September 2024</p> <p>Time: 11:30 - 13:00 (SAST)</p> <p>Meeting Details: MS Teams Link Meeting ID: 366 596 056 377 Passcode: SA5Fwm</p> |
| <p>Agenda</p> | |
| <ul style="list-style-type: none"> - General information on the SAVax Programme - Background to Call for Proposals - Priority areas for the Call (Focus Areas and Scope) - Target Beneficiaries and Eligibility Criteria - Grant Size and Grantee Contribution - Number of applications and applicants per grant - Eligibility of lead and co-applicants - Eligibility of costs - Ineligible costs - Ethics clauses and Code of Conduct - Visibility - How to apply and procedures to follow - Selection process and timelines - Technical scoring - Pre-award checks - Intellectual Property | |
| <ul style="list-style-type: none"> - Questions from Participants | |



Appendix 3: Frequently Asked Questions

| Frequently Asked Questions (FAQ) | |
|---|--|
| Question | Answer |
| How many grants will be awarded in this call? | The GIZ seeks to award up to 6 grants to eligible proposals for up to EUR 350 000 per proposal. |
| Can profit making legal entities participate as lead applicant, co-applicants or affiliated entities? | <p>Yes. Grant agreements and contracting are subject to an assessment of whether the potential recipient is commercially, administratively and legally qualified to assume responsibility for implementing the activities and milestones proposed.</p> <p>Privat sector grant recipients may only recover actual costs and only for public-benefit activities.</p> |
| Where can the application forms be downloaded from? | <p>Application forms, guidelines, and templates needed to apply for the grant can be downloaded from the link below:</p> <p>https://www.giz.de/en/worldwide/154595.html</p> <p>Guidelines for Applicants: Contains the basis of the call for proposals, including aspects such as the eligible activities, eligible costs, eligible applicants, financing requirements. It is the main document guiding the applicants in preparing their applications.</p> <p>Templates for submission, which include:</p> <p>Grant Application Form: The Application Form contains all the relevant sections that need to be completed. It must be completed in its entirety with the template provided.</p> <p>Budget Template: This annex must be completed by the applicants. It provides the template for the budget proposed.</p> |
| Where should applications be submitted? | All applications and supporting documentation should be submitted via the KOBO Toolbox portal. |
| Where can queries be directed? | Any queries can be directed to the dedicated email address savaxjointaction@giz.de . |

| | |
|--|--|
| <p>Can the action proposed be financed by other donors/grants?</p> | <p>No. All project activities and milestones included in the project application and proposal need to be achievable within the proposed budget.</p> |
| <p>Is the procurement of goods, (including equipment), services, works an eligible activity?</p> | <p>Yes. Procurement of goods, (including equipment), and services, are eligible if they will facilitate the achievement of the milestones and objectives as detailed in the proposal and will not be the only activity under the proposed action. Any procurement under the proposed budget must be conducted following GIZ procurement standards.</p> <p>Please see procurement and relevant financial guidelines.</p> |
| <p>Are the co-applicants and affiliated entities signatories of the grant contract?</p> | <p>Only the lead applicant is signatory to the contract.</p> <p>Lead- and Co-Applicants are encouraged to agree beforehand on the activities implemented by each party. In addition, if possible, this relationship should be established and confirmed through a legal instrument such as a consortium agreement, memorandum of understanding, collaboration agreement or similar mechanism.</p> |
| <p>Value Added Tax (VAT)</p> | <p>The Recipient shall declare whether or not invoiced VAT amounts resulting from the purchase of goods and services in connection with the use of the Grant are generally deductible for the Recipient.</p> <p>The Recipient shall establish the formal requirements for an input VAT deduction, as far as legally possible.</p> <p>VAT amounts can only be reimbursed to the Recipient under the following conditions:</p> <ul style="list-style-type: none"> - the Recipient provides an invoice document with VAT amounts clearly shown; - the invoice is addressed to the Recipient; - the supply of goods or services underlying the invoice is subject to VAT in accordance with the legal regulations; - the Recipient is not entitled to deduct the VAT amounts in connection with the use of the Grant. - However, VAT amounts are not reimbursed if the Recipient is generally entitled to deduct input VAT amounts in connection with the use of the Grant but the requirements for an input VAT deduction have not been established by the Recipient. In case of doubt, contacting a tax advisor is recommended. |

Appendix 4: Kobo Toolbox Instructions

1. **Signal Bars:** The signal bars indicate whether the form can be launched offline or not. Web forms are built to be able to collect data while you are offline, however, it is essential to visit the form URL with an internet connection before going offline. Once your form has been loaded and cached, you'll see the offline availability icon (empty "signal bars" and a check mark) in the top-left corner indicating that you can now access the form offline.
2. **Printer Icon:** The printer icon provides you access to print your form or save it as a PDF version. For this, press the printer icon and then select Destination (an appropriate printer connected to your device to print out your survey form or Save as PDF to save your survey form as a PDF).
3. **Save as Draft:** Use this feature to edit or update your records before submitting it to the KoboToolbox server. Once you have checked Save as Draft you will have an option to Save Draft. The draft record gets queued but does not sync with KoboToolbox server. To sync it with the server you will have to open the record from the queued list and uncheck Save as Draft and press Submit.
4. **Submit:** Press the Submit button if you have completed collecting information and wish to send the filled-up form to the KoboToolbox server. After pressing the Submit button, you will not have an option to edit the records on your device.
5. **Queued Records Counter:** The Queued Records Counter shows you the total number of records submitted and waiting to be uploaded to a server. The queued records are uploaded automatically in the background every 5 minutes when the web page is open, and an internet connection is available.
6. **Queue Records Pane:** Clicking the side button shows you the records that are available as drafts (which can still be edited) and finalized submitted records queued to be either uploaded to your server with an internet connection or exported as zip file as outlined in the [support article here](#).



SAVax Joint Action Competitive Call for Proposals

- ▶ **Instructions**
- ▶ **Eligibility**
- ▶ **Lead Applicant Details**
- ▶ **Co-Applicant Details**
- ▶ **Project Details**
- ▶ **Budget and Financing**
- ▶ **Commercial Suitability Assessment - Lead Applicant**
- ▶ **Commercial Suitability Assessment - Co-Applicant(s)**

